| human | Q5 |
| P496 | ORCID iD | 0000-0003-3818-8531 |
| P106 | occupation | researcher | Q1650915 |
| Q92775024 | 4-Hydroxytamoxifen enhances sensitivity of estrogen receptor α-positive breast cancer to docetaxel in an estrogen and ZNF423 SNP-dependent fashion |
| Q90315310 | A Transcriptionally Definable Subgroup of Triple-Negative Breast and Ovarian Cancer Samples Shows Sensitivity to HSP90 Inhibition |
| Q47137286 | A comprehensive analysis of breast cancer microbiota and host gene expression. |
| Q28943270 | A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303 |
| Q35082982 | A polygenic risk score for breast cancer in women receiving tamoxifen or raloxifene on NSABP P-1 and P-2. |
| Q64389037 | ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer |
| Q91069671 | Anastrozole Aromatase Inhibitor Plasma Drug Concentration Genome-Wide Association Study: Functional Epistatic Interaction Between SLC38A7 and ALPPL2 |
| Q89881422 | Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor α |
| Q34265045 | Aromatase inhibitor-associated bone fractures: a case-cohort GWAS and functional genomics |
| Q36245513 | Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression |
| Q51761102 | Association of the Polygenic Scores for Personality Traits and Response to Selective Serotonin Reuptake Inhibitors in Patients with Major Depressive Disorder. |
| Q97418604 | Author Correction: Regulation of sister chromatid cohesion by nuclear PD-L1 |
| Q56968709 | BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study |
| Q47659995 | Beta-defensin 1, aryl hydrocarbon receptor and plasma kynurenine in major depressive disorder: metabolomics-informed genomics. |
| Q41483871 | Breast cancer chemoprevention pharmacogenomics: Deep sequencing and functional genomics of the ZNF423 and CTSO genes |
| Q36841465 | Breast cancer risk reduction and membrane-bound catechol O-methyltransferase genetic polymorphisms |
| Q37581544 | CDK4/6-dependent activation of DUB3 regulates cancer metastasis through SNAIL1. |
| Q101210788 | CRM1 inhibitor anti-tumor activity is enhanced with salicylates by S-phase arrest and impaired DNA-damage repair |
| Q41460767 | Calmodulin-like protein 3 is an estrogen receptor alpha coregulator for gene expression and drug response in a SNP, estrogen, and SERM-dependent fashion |
| Q37042605 | Clonal expansion of antitumor T cells in breast cancer correlates with response to neoadjuvant chemotherapy |
| Q92397645 | Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol) |
| Q92539936 | Comparison of 99mTc-Sestamibi Molecular Breast Imaging and Breast MRI in Patients With Invasive Breast Cancer Receiving Neoadjuvant Chemotherapy |
| Q28252663 | Cytosolic 5'-nucleotidase III (NT5C3): gene sequence variation and functional genomics |
| Q88511739 | DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine |
| Q92846158 | Deep sequencing across germline genome-wide association study signals relating to breast cancer events in women receiving aromatase inhibitors for adjuvant therapy of early breast cancer |
| Q48241016 | Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation |
| Q52720231 | Discovery of a glucocorticoid receptor (GR) activity signature using selective GR antagonism in ER-negative breast cancer. |
| Q34359524 | Ecto-5'-nucleotidase and thiopurine cellular circulation: association with cytotoxicity |
| Q47137308 | Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study |
| Q36632405 | Estrogen, SNP-Dependent Chemokine Expression and Selective Estrogen Receptor Modulator Regulation |
| Q35118969 | Estrogens and their precursors in postmenopausal women with early breast cancer receiving anastrozole |
| Q36025853 | Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy |
| Q37199719 | FKBP5 genetic variation: association with selective serotonin reuptake inhibitor treatment outcomes in major depressive disorder |
| Q33584258 | Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors |
| Q44548365 | Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy |
| Q34488758 | Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors |
| Q88693944 | Germline genome-wide association studies in women receiving neoadjuvant chemotherapy with or without bevacizumab |
| Q56889635 | HGT-ID: an efficient and sensitive workflow to detect human-viral insertion sites using next-generation sequencing data |
| Q114015275 | Implementation of preemptive DNA sequence–based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study |
| Q52604451 | Ketamine and ketamine metabolites as novel estrogen receptor ligands: Induction of cytochrome P450 and AMPA glutamate receptor gene expression. |
| Q61228549 | MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1 |
| Q112577500 | Multi-omics driven predictions of response to acute phase combination antidepressant therapy: a machine learning approach with cross-trial replication |
| Q58765230 | NOTCH3 expression is linked to breast cancer seeding and distant metastasis |
| Q91085591 | PANOPLY: Omics-Guided Drug Prioritization Method Tailored to an Individual Patient |
| Q47755674 | Pharmacogenomic Discovery to Function and Mechanism: Breast Cancer as a Case Study |
| Q97677274 | Pharmacogenomics of aromatase inhibitors in postmenopausal breast cancer and additional mechanisms of anastrozole action |
| Q112292428 | Quantitative Analysis of Tyrosine Phosphorylation from FFPE Tissues Reveals Patient-Specific Signaling Networks |
| Q94461827 | Regulation of sister chromatid cohesion by nuclear PD-L1 |
| Q55017654 | SLCO1B1 polymorphisms and plasma estrone conjugates in postmenopausal women with ER+ breast cancer: genome-wide association studies of the estrone pathway. |
| Q42703024 | SNPs near the cysteine proteinase cathepsin O gene (CTSO) determine tamoxifen sensitivity in ERα-positive breast cancer through regulation of BRCA1 |
| Q37009636 | Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention |
| Q97564747 | Single-nucleotide polymorphism biomarkers of adjuvant anastrozole-induced estrogen suppression in early breast cancer |
| Q92971607 | Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall |
| Q88313233 | TCL1A Single-Nucleotide Polymorphisms and Estrogen-Mediated Toll-Like Receptor-MYD88-Dependent Nuclear Factor-κB Activation: Single-Nucleotide Polymorphism- and Selective Estrogen Receptor Modulator-Dependent Modification of Inflammation and Immune |
| Q51415655 | TCL1A, a novel transcription factor and a co-regulator of NF-кB p65: SNP and estrogen-dependence. |
| Q36714877 | TSPYL5 SNPs: association with plasma estradiol concentrations and aromatase expression |
| Q64079299 | The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1 |
| Q61443907 | The novel function of tumor protein D54 in regulating pyruvate dehydrogenase and metformin cytotoxicity in breast cancer |
| Q33614238 | Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer |
| Q91264728 | Tyrosine Phosphorylation of Mitochondrial Creatine Kinase 1 Enhances a Druggable Tumor Energy Shuttle Pathway |
Search more.